ZYBERNO
Stock Report
Updated Sep 1, 2026

Incannex Healthcare Inc. (IXHL)

Healthcare • NASDAQ

$3.35

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
Incannex Healthcare Inc. (IXHL) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-81.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-2,118.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Incannex Healthcare Inc. (IXHL) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, IXHL generated -$19.61M in Owner Earnings. Reinvestment rate: 751,691.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.35
Market Cap:$41.37M

Valuation Multiples (3)

P/B Ratio:0.55x
P/S Ratio:481.02x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:-$32.97M
Ev Ebitda Ratio:0.00x

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (5)

ROA:-76.1%
Reinvestment Rate:751,691.9%
Fundamental Growth Rate (g):-15,924,275.3%

Margin Analysis (1)

Ebitda Margin:166,326,219.8%

Yield Metrics (2)

Earnings Yield:-$28.13
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:41.56x
Quick Ratio:41.56x
Cash Ratio:38.64x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:0.00x

Coverage Ratios (2)

Interest Coverage Ratio:-81.19x
Times Interest Earned:-81.19

Capital Structure (4)

Working Capital:78,168,000.00
Cash And Cash Equivalents:74,450,000.00
Long Term Debt:$42.00K
Net Debt:-$74.34M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$86.00K
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$25.37M

Bottom Line Performance (3)

-$48.41M
Income Before Tax:-$48.41M
Ebitda Ttm:143,040,549,000.00

Operating Expenses (5)

Operating Expenses:25,365,000.00
R And D Expense:7,423,000.00
Sga Expense:17,942,000.00
Income Tax Expense:$0.00
Interest Expense:293,000.00

Expense Ratios (3)

R And D To Revenue Percentage:61,858.3%
Sga To Revenue Percentage:149,516.7%
Ebitda Margin:166,326,219.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$80.28M
Current Assets:$80.10M
Ppe Net:572,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:5,049,000.00
Current Liabilities:1,927,000.00
Long Term Debt:$42.00K
Short Term Debt:$72.00K

Equity & Capital (3)

Equity:$75.23M
Retained Earnings:-$174.37M
Common Stock:800,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:202,000.00

Special Items (2)

Contract Liabilities:30,000.00
Stock Based Compensation:-1,468,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$19.48M-$19.70M

Investment Activities (1)

Investing Cash Flow:-$42.00K

Financing Activities (3)

Financing Cash Flow:$67.18M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:69,465,000.00
Long Term Debt Issuance:$2.88B
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:143,065,914,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.92
-$0.92
Earnings Per Share Ttm:-$3.92

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$1.01

Book Value & Capital (2)

Book Value Per Share:$6.09
Cash Per Share:6.03

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:857.33
Cash Conversion Cycle:-2,855.33
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$19.61M

Damodaran Growth Analysis (2)

Reinvestment Rate:751,691.9%
Fundamental Growth Rate (g):-15,924,275.3%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):100.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:IXHL
Company Name:Incannex Healthcare Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:12.35M
Shares Outstanding Basic:12.35M
Shares Outstanding Diluted:12.35M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 04:24:53 UTC
Data Timestamp:2026-08-20T13:22:45.311494
Scroll to Top